The oral version of Wegovy, a weight loss medication approved by the U.S. Food and Drug Administration (FDA), is now available to the public. The pill form of semaglutide, previously only available as an injection, offers a more convenient option for patients seeking medical assistance with weight management. Analysts project high demand, though cost and insurance coverage may limit accessibility.
Wegovy, developed by Novo Nordisk, has been shown in clinical trials to help patients lose an average of 15% of their body weight when combined with diet and exercise. The oral formulation underwent rigorous testing, with results published in peer-reviewed journals. Sources familiar with the rollout confirm that pharmacies have begun stocking the medication, though availability may vary by location.
“The introduction of an oral version addresses one of the main barriers to adherence—the discomfort associated with injections,” said a healthcare analyst familiar with the drug’s development. However, the cost remains a concern, with estimates suggesting a monthly price tag of over $1,000 without insurance coverage.
Looking ahead, experts anticipate that demand for Wegovy could strain supply chains, similar to shortages seen with the injectable version. Insurance providers are also expected to scrutinize coverage criteria, potentially limiting access for some patients.